BURNABY, British Columbia--(BUSINESS WIRE)--The Government of Saskatchewan expands public coverage for Dexcom Continuous Glucose Monitoring Systems.
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Jon Coleman as Chief Commercial Officer.
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platfo
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write th
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Market corrections, like the recent dip, are normal and temporary, with historical data showing average declines of 13-14% since 1950. Long-term investors should stay the course. Corrections often lea
Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. The post Why Dexcom Is On A Six-Day Losing Spree — But This An
It might be tempting to pull your money out of the S&P 500 given President Trump's trade-war mongering. The post Analysts Say 6 Rising Stocks Are Your Best Bets Amid Trump appeared first on Investor's
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down near
DexCom, Inc. (NASDAQ:DXCM ) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of

3 Growth Stocks to Buy and Hold Forever

06:14pm, Saturday, 01'st Mar 2025
The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth stocks to own for the long term. As these companies steadily grow their revenue and
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE